In addition to directly inhibiting HER2, their mechanism of action also involves antibody-dependent cell-mediated cytotoxicity (ADCC), and changes in the immune environment after having COVID-19 may have an impact on the effects of the above drugs (25). Here, ERBB2 is linked to COVID-19.